Brazikumab Biosimilar - Research Grade

Human

IL23A

>1mg/ml

IgG2 - lambda

CHO Cells

Guselkumab Biosimilar - Research Grade (ICH5064), Risankizumab Biosimilar - Research Grade (ICH5210), Tildrakizumab Biosimilar - Research Grade (ICH5303), Mirikizumab Biosimilar - Research Grade (ICH5683), Picankibart Biosimilar - Research Grade (ICH5772)

https://www.imgt.org/mAb-DB/

ICH3002

Q9NPF7

51561

Blue ice

This product is a research-grade biosimilar of brazikumab (also known as AMG 139/MEDI2070), supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is built to recapitulate the target specificity of the originator, a fully human IgG2-lambda monoclonal antibody directed against the p19 subunit of interleukin-23 (encoded by IL23A, UniProt Q9NPF7). The originator drug was developed as a selective IL-23 inhibitor and evaluated clinically in moderate-to-severe Crohn's disease and other immune-mediated inflammatory conditions. As a biosimilar reagent, this material is intended for in-vitro and functional laboratory applications rather than any clinical or diagnostic use. It is manufactured to research quality with low endotoxin and is available in bulk milligram-to-gram quantities, making it suitable as a reference or comparator antibody in binding, neutralisation, and assay-development workflows. Because it reproduces the originator's IL-23p19 specificity without any conjugation or therapeutic formulation, it serves as a defined, consistent tool for studying IL-23 biology and for benchmarking anti-IL-23 antibody characterisation. IL-23 is a heterodimeric pro-inflammatory cytokine composed of a unique p19 subunit (IL23A, the target here) covalently paired with the p40 subunit (IL12B) that it shares with IL-12. Brazikumab binds the p19 subunit selectively, so it neutralises IL-23 without affecting IL-12. IL-23 signals through a receptor complex of IL23R and IL12RB1, activating JAK2/TYK2 and STAT3 to drive the differentiation, expansion, and maintenance of Th17 cells and other IL-17-producing populations. This IL-23/Th17 axis is central to mucosal and tissue inflammation, and its dysregulation is implicated in Crohn's disease, ulcerative colitis, psoriasis, and related immune-mediated disorders. Selective p19 blockade is therefore an attractive strategy for dampening IL-23-driven inflammation while preserving IL-12-dependent Th1 immunity.

IL-23 subunit alpha, Interleukin-23 subunit p19, IL-23p19, Interleukin-23 subunit alpha, SGRF

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Brazikumab (anti-IL23A) Biosimilar

Q: Is the Brazikumab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Brazikumab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Brazikumab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Brazikumab that binds IL23A; for research use only.